Table 1.
Demographics: contemporaneous and prospective KIR DS trial cohorts
| Contemporaneous cohort | Prospective KIR DS trial | |||
|---|---|---|---|---|
| RIC/NMA | MAC | RIC/NMA | MAC | |
| N | 987 | 1432 | 96 | 147 |
| No. of centers | 98 | 109 | 10 | 15 |
| Recipient age, y | ||||
| Median (range) | 64 (20-84) | 49 (20-76) | 65 (28-78) | 51 (20-75) |
| Recipient race/ethnicity | ||||
| White, non-Hispanic | 897 (93) | 1250 (89) | 93 (97) | 139 (95) |
| Recipient sex | ||||
| Male | 544 (55) | 707 (49) | 54 (56) | 73 (50) |
| Female | 443 (45) | 725 (51) | 42 (44) | 74 (50) |
| Karnofsky performance score | ||||
| 90-100 | 525 (53) | 987 (69) | 55 (57) | 98 (67) |
| 10-80 | 450 (46) | 425 (30) | 41 (43) | 49 (33) |
| HCT–comorbidity index scores | ||||
| 0 | 210 (21) | 401 (28) | 13 (14) | 26 (18) |
| 1-3 | 502 (51) | 756 (53) | 51 (59) | 67 (46) |
| 4+ | 272 (28) | 274 (19) | 26 (27) | 54 (37) |
| Recipient CMV serostatus | ||||
| Negative | 335 (34) | 460 (32) | 39 (42) | 61 (43) |
| Positive | 645 (66) | 962 (68) | 53 (58) | 81 (57) |
| Donor:recipient HLA allele match | ||||
| 8/8 | 849 (86) | 1196 (84) | 88 (92) | 135 (92) |
| 7/8 | 138 (14) | 236 (16) | 8 (8) | 11 (7) |
| HLA DP matching | ||||
| Fully matched | 164 (17) | 240 (17) | 14 (18) | 29 (23) |
| Permissive mismatch | 481 (49) | 687 (48) | 43 (54) | 55 (44) |
| Nonpermissive mismatch | 340 (36) | 501 (35) | 23 (29) | 40 (32) |
| Recipient C1 allele present | ||||
| Yes | 866 (88) | 1213 (85) | 84 (88) | 122 (83) |
| Graft type | ||||
| Marrow | 79 (8) | 274 (19) | 11 (11) | 33 (22) |
| PBSC | 908 (92) | 1158 (81) | 85 (89) | 114 (78) |
| Donor age | ||||
| Median (range), y | 28 (18-61) | 29 (18-61) | 23 (23-23) | 39 (27-50) |
| Conditioning regimen groups | ||||
| RIC/NMA: TBI ± other | 177 (18) | 29 (30) | ||
| RIC/NMA: Flu/Clof ± other | 399 (40) | 5 (5) | ||
| RIC/NMA: alkylator based | 411 (42) | 62 (65) | ||
| MAC: TBI ± Bu or Cy or other | 269 (19) | 20 (14) | ||
| MAC: non-TBI | 1164 (81) | 127 (86) | ||
| ATG/alemtuzumab use | ||||
| ATG + alemtuzumab | 0 (0) | 1 (< 1) | 0 (0) | 0 (0) |
| ATG alone | 385 (39) | 569 (40) | 27 (28) | 24 (16) |
| Alemtuzumab alone | 39 (4) | 25 (2) | 4 (4) | 7 (5) |
| No ATG or alemtuzumab | 562 (57) | 836 (58) | 65 (68) | 116 (79) |
| Disease status at transplant | ||||
| Early | 777 (79) | 1084 (76) | 69 (72) | 79 (54) |
| Intermediate | 210 (21) | 348 (24) | 13 (14) | 28 (19) |
| Advanced | 0 (0) | 0 (0) | 14 (15) | 40 (27) |
| Cytogenetics | ||||
| Good | 35 (10) | 108 (20) | 6 (7) | 10 (8) |
| Intermediate | 255 (72) | 331 (62) | 63 (69) | 92 (70) |
| Poor | 64 (18) | 97 (18) | 22 (24) | 29 (22) |
| Unknown, n | 633 | 896 | 5 | 16 |
| Follow-up among survivors, mo | ||||
| No. evaluated | 440 | 759 | 48 | 74 |
| Median (range) | 38 (6-99) | 46 (2-98) | 36 (12-73) | 36 (12-72) |
| Donor KIR haplotype | ||||
| AA | 319 (32) | 454 (32) | 18 (22) | 39 (29) |
| B/x | 668 (68) | 978 (68) | 65 (78) | 96 (71) |
| Donor centromeric region score | ||||
| AA | 455 (46) | 689 (48) | 32 (39) | 61 (45) |
| AB | 442 (45) | 594 (41) | 43 (52) | 58 (43) |
| BB | 90 (9) | 149 (10) | 8 (10) | 16 (12) |
Values are n (%) unless otherwise noted.
Bu, busulfan; Clof, clofarabine; Cy, cyclophosphamide; Flu, fludarabine.